Pelthos Therapeutics Inc. (PTHS) is a publicly traded company in the Unknown sector. Across all available filings, 6 corporate insiders have executed 14 transactions totaling $280.3K, demonstrating a bearish sentiment with -$280.3K in net insider flow. The most recent transaction on Dec 23, 2025 involved a transaction of 12,000 shares valued at $0.
No significant insider buying has been recorded for PTHS in the recent period.
No significant insider selling has been recorded for PTHS in the recent period.
Based on recent SEC filings, insider sentiment for PTHS is bearish with an Insider Alignment Score of 0/100 and a net flow of -$280.3K. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Pelthos Therapeutics Inc. (PTHS) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 6 insiders are actively trading PTHS stock, having executed 14 transactions in the past 90 days. The most active insider is Pharmaceuticals Inc Ligand (Executive), who has made 1 transactions totaling $15.0M.
Get notified when executives and directors at PTHS file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Dec 23, 2025 | J. Einhorn Andrew | Executive | Award | 12,000 | $N/A | $0 | |
| Dec 23, 2025 | J. Einhorn Andrew | Executive | Award | 12,000 | $N/A | $0 | |
| Dec 10, 2025 | Pauls Matthew | Executive | Gift | 9,542 | $N/A | $0 | |
| Nov 25, 2025 | M. Friedberg Ezra | Executive | Sale | 2,000 | $28.14 | $56.3K | |
| Nov 25, 2025 | M. Friedberg Ezra | Executive | Sale | 1 | $28.50 | $29 | |
| Nov 25, 2025 | M. Friedberg Ezra | Executive | Sale | 2,000 | $28.01 | $56.0K | |
| Nov 25, 2025 | M. Friedberg Ezra | Executive | Sale | 5,999 | $28.00 | $168.0K | |
| Oct 2, 2025 | Pauls Matthew | Executive | Option Exercise | 2,123 | $N/A | $0 | |
| Jul 2, 2025 | Pauls Matthew | Executive | Option Exercise | 8,493 | $N/A | $0 | |
| Jul 1, 2025 | Inc Ligand Pharmaceuticals | Executive | Conversion | 1,500,000 | $10.00 | $15.0M | Large |
| Jul 1, 2025 | C. Davis Todd | Executive | Conversion | 1,500,000 | $10.00 | $15.0M | Large |
| Jul 1, 2025 | Francis Knuettel II | Executive | Conversion | 10,000 | $10.00 | $100.0K | |
| Jul 1, 2025 | M. Friedberg Ezra | Executive | Conversion | 40,000 | $10.00 | $400.0K | |
| Jul 1, 2025 | M. Friedberg Ezra | Executive | Conversion | 40,000 | $10.00 | $400.0K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Conversion(C) | 5 | $30.9M | 99.1% |
Sale(S) | 4 | $280.3K | 0.9% |
Award(A) | 2 | $0 | 0.0% |
Gift(G) | 1 | $0 | 0.0% |
Exercise(M) | 2 | $0 | 0.0% |
Insider selling pressure at Pelthos Therapeutics Inc. has increased, with 6 insiders executing 14 transactions across all time. Total sales of $280.3K significantly outpace purchases of $0, resulting in a net outflow of $280.3K. This selling activity appears largely discretionary, which may warrant closer attention from investors.